MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue----
Cost of Revenue-67,314106,765121,033
Gross Profit--67,314-106,765-121,033
Operating Expenses
Research Development49,97449,97449,97449,974
Selling General and Administrative15,60128,45232,05224,048
Non Recurring----
Others----
Total Operating Expenses65,57595,766138,817145,081
Operating Income or Loss-65,575-95,766-138,817-145,081
Income from Continuing Operations
Total Other Income/Expenses Net-2,887-22,637-30,691-17,753
Earnings Before Interest and Taxes-65,575-95,766-138,817-145,081
Interest Expense-956-34,650-22,449-18,769
Income Before Tax-68,462-118,403-169,508-162,834
Income Tax Expense-7,695-42,399-13,224-11,215
Minority Interest---1,539239
Net Income From Continuing Ops-60,767-76,004-156,284-151,619
Non-recurring Events
Discontinued Operations20,261546,8722,7663,832
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-40,506472,028-151,740-147,957
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-40,506472,028-151,740-147,957